From the viewpoints of key players in industry and academia, our panel will discuss the approval and its implications, including why it was controversial, the opportunities it brings, and the key steps the industry can take to forge the path ahead to developing earlier diagnoses and affordable therapies for the over 35 million Alzheimer’s Disease sufferers around the world.
- The opportunities ahead spurred by the Aduhelm approval
- What it means for Alzheimer’s patients
- Key steps academia and industry can take to forge the path ahead
- Implications for other approaches and neurodegenerative disease areas
A 30 minute lecture by Em.Prof. Romeny was followed by a chat with his former students, Vesna Prčkovska, CEO, and Paulo Rodriguez, CTO of QMENTA.
- How we can bridge the gap between biological and AI communities
- New optical and physiological recording techniques in imaging analysis
- Practical applications with respect to computer vision and machine learning
- Innovate to develop products and services.
- Engage better with patients and partners.
- Execute operations more effectively.
Webinar: Neurology Clinical Trials Are Failing. How Can We Fix Them?
One billion people worldwide suffer from neurological related disorders with limited therapy options. Over 2000 neurological clinical trials start each year in the US alone. Yet, it is estimated that only 5.9% of Phase I neurology drugs are likely to get FDA approval.
Research innovation such as new biomarkers or advanced algorithms often do not get translated into clinical practice, slowing progress. Adding to that, the scale, inefficiency and subjectivity of neurological clinical trials makes them inherently difficult. Neuroimaging analysis is key to developing new therapies for brain disease but it’s difficult to do.
Webinar: Turbo-charging Neurology Research into Clinical Practice
Translation of neurology research advances into clinical practice is challenged by the difficulty of compliantly collecting, calibrating and processing large scale brain image and related data to derive patient insights.
During this webinar, an esteemed panel of neurology key opinion leaders and innovators will discuss how neurology researchers, AI-tool developers and innovative technology companies can collaborate to turbo-charge the transfer of brain research into clinical practice.
Webinar: Effects of COVID on people with MS
As COVID-19 spreads around the world, the questions from people affected by Multiple sclerosis (MS) and the clinicians who treat them only become more urgent.
QMENTA has been working with MS Data Alliance (MSDA) and MS International Federation (MSIF) in the MS Global Data Sharing Initiative to collect patient data in order to study how COVID-19 is affecting people who suffer from Multiple sclerosis (MS).
On Wednesday 8th July, 2020 a webinar session was held, where Dr. Liesbet Peeters from the MS Data Alliance (MSDA), Dr. Clare Walton from MS International Federation (MSIF) presented the first preliminary results of the initiative. Dr. Pablo Villoslada from Stanford University joined them in a panel discussion to discuss how big data is helping to investigate how COVID-19 affects the people who suffer from MS.
Webinar: IronTract Challenge Round II
The IronTract Challenge has been extended for a second round and is now accepting new participants. The best pre- and post-processing strategies from the highest-scoring teams in Round I will now be provided to all teams. This new challenge focuses on the reproducibility upstream to the reconstruction and tractography methods.
A live webinar was held on Friday, October 9th, 2020 where Anastasia Yendiki and Chiara Maffei from Harvard Medical School gave a brief summary of the previous round and explained how to participate in the second round of the IronTract Challenge.
Gabriel from École polytechnique fédérale de Lausanne, one of the winners of the first round, gave a tutorial on how to submit your code to the QMENTA Inc‘s platform.